Clearbridge Investments LLC raised its position in shares of Integra Lifesciences Holdings Corp (NASDAQ:IART) by 0.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,294,287 shares of the life sciences company’s stock after acquiring an additional 3,561 shares during the quarter. Clearbridge Investments LLC owned about 1.65% of Integra Lifesciences worth $61,945,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently modified their holdings of IART. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Integra Lifesciences by 38.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,806 shares of the life sciences company’s stock valued at $182,000 after purchasing an additional 1,054 shares during the period. Zions Bancorporation acquired a new position in shares of Integra Lifesciences during the third quarter valued at about $205,000. Campbell Newman Asset Management Inc. raised its holdings in shares of Integra Lifesciences by 21.5% during the fourth quarter. Campbell Newman Asset Management Inc. now owns 6,964 shares of the life sciences company’s stock valued at $333,000 after purchasing an additional 1,234 shares during the period. Oppenheimer & Co. Inc. raised its holdings in shares of Integra Lifesciences by 25.2% during the third quarter. Oppenheimer & Co. Inc. now owns 7,293 shares of the life sciences company’s stock valued at $368,000 after purchasing an additional 1,466 shares during the period. Finally, Virtu Financial LLC acquired a new position in shares of Integra Lifesciences during the fourth quarter valued at about $378,000. 90.93% of the stock is currently owned by institutional investors and hedge funds.
In other Integra Lifesciences news, major shareholder Richard E. Caruso sold 32,880 shares of the company’s stock in a transaction dated Thursday, March 8th. The shares were sold at an average price of $53.68, for a total value of $1,764,998.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Christian S. Schade sold 15,658 shares of the company’s stock in a transaction dated Monday, March 5th. The stock was sold at an average price of $52.88, for a total transaction of $827,995.04. Following the completion of the sale, the director now directly owns 75,262 shares of the company’s stock, valued at $3,979,854.56. The disclosure for this sale can be found here. Insiders sold a total of 70,996 shares of company stock worth $3,822,267 in the last 90 days. 21.50% of the stock is currently owned by company insiders.
Integra Lifesciences (NASDAQ:IART) last posted its earnings results on Tuesday, February 27th. The life sciences company reported $0.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.56 by $0.08. Integra Lifesciences had a net margin of 5.45% and a return on equity of 16.94%. The company had revenue of $368.60 million for the quarter, compared to analyst estimates of $362.64 million. During the same quarter in the prior year, the business posted $0.52 EPS. The firm’s revenue was up 44.2% compared to the same quarter last year. analysts expect that Integra Lifesciences Holdings Corp will post 2.33 earnings per share for the current fiscal year.
Several brokerages have recently weighed in on IART. Oppenheimer reiterated a “buy” rating on shares of Integra Lifesciences in a report on Thursday, January 11th. Barclays reiterated a “hold” rating and set a $53.00 price objective on shares of Integra Lifesciences in a report on Tuesday, January 9th. Zacks Investment Research lowered shares of Integra Lifesciences from a “hold” rating to a “sell” rating in a report on Wednesday, December 13th. JMP Securities upped their price objective on shares of Integra Lifesciences from $57.00 to $60.00 and gave the company a “market outperform” rating in a report on Wednesday, February 28th. Finally, TheStreet upgraded shares of Integra Lifesciences from a “c+” rating to a “b-” rating in a report on Wednesday, February 7th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $54.18.
Integra Lifesciences Profile
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra Lifesciences Holdings Corp (NASDAQ:IART).
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.